【摘要】 PD-1抑制剂帕博利珠单抗已作为二线治疗药物用于胸腺鳞状细胞癌治疗。由于胸腺鳞状细胞癌在临床上较为罕见，帕博利珠单抗是否对PD-L1阴性患者治疗有效尚不明确。本研究报道1例接受帕博利珠单抗联合含铂化疗治疗PD-L1阴性且双肺及胸膜多发转移的胸腺鳞状细胞癌患者病例，患者的无病进展生存期延长2倍至9.2个月，且无免疫相关不良反应事件发生。本病例报道旨在为PD-L1阴性胸腺鳞状细胞癌患者临床治疗提供一定的参考价值。更多还原

【Abstract】 Pembrolizumab, a PD-1 inhibitor, has been used as second-line drug in treatment of thymic squamous cell carcinoma. Thymic squamous cell carcinoma is relatively rare in clinical practice, it is unclear whether pembrolizumab is effective for PD-L1 negative patients. The study reported a case of thymic squamous cell carcinoma with PD-L1 negative and multiple lung and pleural metastases treated with pembrolizumab combined with platinum containing chemotherapy. Disease free progression survival period of the patient was approximately doubled to 9.2 months, no immune related adverse events occurred. The case report provides some certain reference value for clinical treatment of PD-L1 negative thymic squamous cell carcinoma patients.更多还原